BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 5361480)

  • 1. Immunoglobulin levels and long-acting thyroid stimulator (LATS) in hyperthyroidism. A preliminary study.
    Yamakido M; Yokoyama M; Noguchi S
    Hawaii Med J; 1969; 29(2):118-9. PubMed ID: 5361480
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cytogenetic studies in patients with thyroiditis and LATS and antibody-positive hyperthyroidism].
    Tolksdorf M; Schemmel K; Mühlenstedt D; Uthgenannt H; Müller W
    Schweiz Med Wochenschr; 1969 Jul; 99(30):1082-5. PubMed ID: 5351142
    [No Abstract]   [Full Text] [Related]  

  • 3. Specific and nonspecific responses in the bioassay of long-acting thyroid stimulator (LATS).
    Chopra IJ; Solomon DH; Limberg NP
    J Clin Endocrinol Metab; 1970 Oct; 31(4):382-90. PubMed ID: 5468701
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-acting thyroid stimulator (LATS) in hyperthyroidism and exophthalmos.
    Friis T
    Dan Med Bull; 1969 Nov; 16(10):294-304. PubMed ID: 5392781
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
    Hardisty CA; Hanford L; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Parallel study of the thyrostimulating factor with prolonged action (LATS) and of circulating anti-thyroglobulin antibodies. Preliminary results].
    Liberti P; De Santis R; Grasso L; Martino E; Pinchera A; Baschieri L
    Folia Endocrinol; 1966 Dec; 19(6):659-66. PubMed ID: 6014021
    [No Abstract]   [Full Text] [Related]  

  • 7. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
    Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
    J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes in LATS and other thyoid autoantibody levels with therapy.
    Kilpatrick JA
    N Z Med J; 1974 Dec; 80(529):495-6. PubMed ID: 4532201
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship of long-acting thyroid stimulator to pretibial myxedema.
    Schermer DR; Roenigk HH; Schumacher OP; McKenzie JM
    Arch Dermatol; 1970 Jul; 102(1):62-7. PubMed ID: 4925011
    [No Abstract]   [Full Text] [Related]  

  • 10. [Absent biological demonstration of "long-acting thyroid stimulator" (LATS) in endemic euthyroid iodine deficiency goiters].
    Stelzer M; Mertz DP
    Munch Med Wochenschr; 1969 Jun; 111(23):1306-9. PubMed ID: 5820134
    [No Abstract]   [Full Text] [Related]  

  • 11. [The long acting thyroid stimulator (LATS) in some thyroid diseases. Preliminary results].
    Busnardo B; Accordi F; Debiasi S
    Acta Isot (Padova); 1968 Oct; 8(2):165-79. PubMed ID: 5761578
    [No Abstract]   [Full Text] [Related]  

  • 12. [Studies on the problem of a relationship between the occurrence of thyroid antibodies and LATS in hyperthyreosis].
    Weissbecker L; Uthgenannt H; Schemmel K; Müller W; Heesen H; Eickenbusch W; Bindeballe W
    Med Klin; 1966 Dec; 61(52):2062-3. PubMed ID: 5999210
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-acting thyroid stimulator (LATS) and immunofluorescent studies in patients with pretibial myxoedema.
    From E; Diederichsen H; Heydenreich G; Nielsen OS
    Dan Med Bull; 1973 Dec; 20(6):188-91. PubMed ID: 4591336
    [No Abstract]   [Full Text] [Related]  

  • 14. [LATS and thyroid antibody level in the blood in Basedow's disease].
    Földes J; Takó J; Bános C; Gesztesi E; Varga I
    Orv Hetil; 1968 Aug; 109(33):1799-804. PubMed ID: 5714825
    [No Abstract]   [Full Text] [Related]  

  • 15. [The etiopathogenic role of long-acting thyroid stimulator in thyrotoxicosis].
    Papazov G; Milanov S; Platonova E
    Vutr Boles; 1972; 11(2):59-62. PubMed ID: 4679953
    [No Abstract]   [Full Text] [Related]  

  • 16. The value of IgG separation for the detection of LATS in human serum.
    Bonnyns M; Vanhaelst L
    Clin Exp Immunol; 1969 May; 4(5):597-601. PubMed ID: 5815122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Human thyroid stimulator (HTS) in thyroid diseases].
    Hu ZY
    Zhonghua Nei Ke Za Zhi; 1984 Aug; 23(8):480-3, 525. PubMed ID: 6548953
    [No Abstract]   [Full Text] [Related]  

  • 18. [TSH and the "long-acting thyroid stimulator" (LATS) in patients with compensated hyperthyroidism].
    zur Mühlen A von ; Hesch RD; von Lilienfeld H; Emrich D
    Acta Endocrinol Suppl (Copenh); 1971; 152():86. PubMed ID: 5313711
    [No Abstract]   [Full Text] [Related]  

  • 19. Isoelectric focusing of long-acting thyroid stimulator (LATS) containing IgG.
    Schleusener H; Adlkofer F; Uher L; Kaper-Czygan S; Kirstaedter HJ
    Horm Metab Res; 1971 May; 3(3):221-2. PubMed ID: 5171402
    [No Abstract]   [Full Text] [Related]  

  • 20. [Long-acting thyroid stimulator (LATS), thyrotropin (TSH) and the pathogenesis of hyperthyroidism].
    Lamberg BA; Gordin A
    Nord Med; 1968 Dec; 80(49):1651-7. PubMed ID: 5757398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.